Neuroscience
From the New York Times website:
Lilly to Buy Insomnia Compound
By THE ASSOCIATED PRESS
Published: October 28, 2004
Filed at 11:21 a.m. ET
INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the rights to an experimental compound the Indianapolis-based drug maker hopes can become its first product to treat insomnia.
The compound, discovered by Merck KGaA, has the potential to be a new way to treat sleep disorder, without being addictive or causing unwelcome side effects, said Darryle D. Schoepp, vice president of neuroscience discovery research at Lilly.
"This could be really a very important medical advance in the treatment of sleep disorders,'" he said Wednesday.
In addition to purchasing the compound, Lilly will make milestone payments to Merck as the drug moves through testing, plus pay royalties on any sales. Merck keeps rights to co-promote the compound in certain countries.
Called EMD 281014, the molecule has undergone the first stage of human testing -- tests that showed it is safe in humans, Schoepp said.
[ ... Read the full article ... ]. (free registration required)
- Alzheimer's Disease: Amyvid News
One of the number of media reports about today's Amyvid news: Lilly fails to persuade Medicare to pay for Alzheimer's imaging drug September 30, 2013 By Tracy Staton FiercePharmaRead article [snippet] "The Centers for Medicare & Medicaid Services...
- Multiple Sclerosis Clinical Trials
Novartis, Merck KGaA Pills Bring ‘New Horizon’ for MS (Update1) By Naomi Kresge Bloomberg 20 January 2010 "Jan. 20 (Bloomberg) -- The first oral medicines for multiple sclerosis from Novartis AG and Merck KGaA may offer patients who are willing to...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...
- Business World: Ecopia's Eco-4601 And The Blood-brain Barrier
This corporate press release on BusinessWire about a drug candidate for treatment of primary brain tumors: Ecopia's Lead Cancer Compound Shown to Cross Blood-Brain Barrier September 23, 2004 08:26 AM US Eastern Timezone ...
- Pharmaceutical Clinical Trials: Merck
From The New York Times (06 September 2004; free registration required): Merck Says It Will Post the Results of All Drug Trials By GARDINER HARRIS Merck & Company says it will post the results of its clinical trials on drugs on a Web site run by...
Neuroscience
Business World: EMD 281014 and Insomnia
From the New York Times website:
Lilly to Buy Insomnia Compound
By THE ASSOCIATED PRESS
Published: October 28, 2004
Filed at 11:21 a.m. ET
INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the rights to an experimental compound the Indianapolis-based drug maker hopes can become its first product to treat insomnia.
The compound, discovered by Merck KGaA, has the potential to be a new way to treat sleep disorder, without being addictive or causing unwelcome side effects, said Darryle D. Schoepp, vice president of neuroscience discovery research at Lilly.
"This could be really a very important medical advance in the treatment of sleep disorders,'" he said Wednesday.
In addition to purchasing the compound, Lilly will make milestone payments to Merck as the drug moves through testing, plus pay royalties on any sales. Merck keeps rights to co-promote the compound in certain countries.
Called EMD 281014, the molecule has undergone the first stage of human testing -- tests that showed it is safe in humans, Schoepp said.
[ ... Read the full article ... ]. (free registration required)
- Alzheimer's Disease: Amyvid News
One of the number of media reports about today's Amyvid news: Lilly fails to persuade Medicare to pay for Alzheimer's imaging drug September 30, 2013 By Tracy Staton FiercePharmaRead article [snippet] "The Centers for Medicare & Medicaid Services...
- Multiple Sclerosis Clinical Trials
Novartis, Merck KGaA Pills Bring ‘New Horizon’ for MS (Update1) By Naomi Kresge Bloomberg 20 January 2010 "Jan. 20 (Bloomberg) -- The first oral medicines for multiple sclerosis from Novartis AG and Merck KGaA may offer patients who are willing to...
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:New entries shake insomnia market's slumber Reuters ...
- Business World: Ecopia's Eco-4601 And The Blood-brain Barrier
This corporate press release on BusinessWire about a drug candidate for treatment of primary brain tumors: Ecopia's Lead Cancer Compound Shown to Cross Blood-Brain Barrier September 23, 2004 08:26 AM US Eastern Timezone ...
- Pharmaceutical Clinical Trials: Merck
From The New York Times (06 September 2004; free registration required): Merck Says It Will Post the Results of All Drug Trials By GARDINER HARRIS Merck & Company says it will post the results of its clinical trials on drugs on a Web site run by...